Here's Why Acadia Pharmaceuticals Inc. Is Soaring Today
In response to Acadia Pharmaceuticals (NASDAQ: ACAD) reporting blow-out earnings and sharing upbeat guidance, shares of the commercial-stage biopharma, which focuses on diseases of the central nervous system, were trading 13.9% higher as of 1:35 p.m. EDT on Wednesday.
Here's a review of the key financial numbers from the second quarter:
Acadia also shared a few non-financial highlights from the quarter with investors:
Source: Fool.com
Acadia Pharmaceuticals Stock
€24.33
-1.180%
With 28 Buy predictions and not a single Sell prediction Acadia Pharmaceuticals is an absolute favorite of our community.
As a result the target price of 29 € shows a slightly positive potential of 19.19% compared to the current price of 24.33 € for Acadia Pharmaceuticals.
